Syndax Pharmaceuticals, Inc. Proceeds from Debt, Net of Issuance Costs
Syndax Pharmaceuticals, Inc. (SNDX) reported Proceeds from Debt, Net of Issuance Costs of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2023-02-28
- Syndax Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for the quarter ending 2020-12-31 was $0.00.
- Syndax Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for the quarter ending 2020-09-30 was $0.00.
- Syndax Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for the quarter ending 2020-06-30 was $0.00.
- Syndax Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for the quarter ending 2020-03-31 was $19.73M.
- Syndax Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for fiscal 2022 was $0.00.
- Syndax Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Syndax Pharmaceuticals, Inc. proceeds from debt, net of issuance costs for fiscal 2020 was $19.73M.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $19.73M 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $19.73M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $19.73M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $19.73M 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |